Application of patient-derived tumor organoids in the development of anti-tumor drugs
The development of anti-tumor drugs has long faced challenges such as lengthy development cycles, significant variability in drug efficacy in vivo, and differences in effectiveness among individuals.Patient-derived tumor organoids (PDTO) are three-dimensional cultures of tumor cells that can be expanded for a long time, simulating the characteristics of in vivo tumors and tumor cell heterogeneity.In recent years, PDTOs have shown great potential in the field of high-throughput drug screening and personalized medicine.This article reviews the construction of PDTO models and their application in anti-tumor drug screening, new drug research and development, and the current issues faced in this field, aiming to provide a reference for in-depth research in the pharmaceutical industry and related areas of tumor biology.
tumor organoidsanti-tumor drug developmenthigh-throughput drug screeningpersonalized medicine
万方数据
维普
